Unity Biotechnology
UBX1325, a senolytic small molecule that selectively clears senescent cells
- Sector
- Biotech
- Founded
- 2009
- Latest Form D
- $55M, Mar 2018
- Total capital
- $166M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $166M
- 5 Form D · last Mar 2018
- 103 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 24
- 16 pending · first 2018
- Rank in peer group#71 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$55M
- Private capital raisedForm D · SEC · 4th filing$108M
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$500
- Private capital raisedForm D · SEC · 1st filing$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#71 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bob GoeltzExecutive OfficerNamed in SEC Form D filings
- Camille E. SamuelsDirectorNamed in SEC Form D filings
- Dan E. MarquessExecutive OfficerNamed in SEC Form D filings
- Graham E. CooperDirectorNamed in SEC Form D filings
- Jamie E. DananbergExecutive OfficerNamed in SEC Form D filings
- John E. SmitherExecutive OfficerNamed in SEC Form D filings
Show all 14 people
- Keith E. KleinExecutive OfficerNamed in SEC Form D filings
- Keith LeonardExecutive Officer, DirectorNamed in SEC Form D filings
- Kristina E. BurowDirectorNamed in SEC Form D filings
- Nathaniel E. DavidExecutive Officer, DirectorNamed in SEC Form D filings
- Nathaniel E. DavidExecutive Officer, DirectorNamed in SEC Form D filings
- Paul BernsDirectorNamed in SEC Form D filings
- Robert NelsenDirectorNamed in SEC Form D filings
- Tamara TompkinsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 24 granted of 40- PendingAntibodies Directed To Tie-2 and VEGF and Methods of UseUSPTOApplication 18856780
- PendingAcyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUSPTOApplication 18999576
- GrantedTreatment of a Senescence-Associated Ocular Disease or Disorder Using a Bcl-xL Selective InhibitorUSPTOUS 12,285,427
Show all 40 patent records
- Antibodies Directed To Tie-2 and VEGF and Methods of UseAug 7, 2025 · Application 18856780Pending
- Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerJun 12, 2025 · Application 18999576Pending
- Treatment of a Senescence-Associated Ocular Disease or Disorder Using a Bcl-xL Selective InhibitorApr 29, 2025 · US 12,285,427Granted
- Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerFeb 11, 2025 · US 12,221,433Granted
- Antibodies Directed To TIE-2 And Methods Of UseJan 14, 2025 · US 12,195,542Granted
- Antibodies Directed to TIE-2 and Methods of UseNov 28, 2024 · Application 18596448Pending
- Methods of Treating Retinal VasculopathiesOct 17, 2024 · Application 18628083Pending
- Methods of Treating Retinal VasculopathiesJul 25, 2024 · Application 18289554Pending
- Methods of Treating Retinal VasculopathiesApr 9, 2024 · US 11,951,115Granted
- Crystalline Solid Meglumine Salt Inhibitor of BCL and Methods of Making and Using SameFeb 8, 2024 · Application 18032944Pending
- Methods of Inhibiting Pathological AngiogenesisJan 9, 2024 · US 11,865,123Granted
- Treating Cognitive Decline And Other Neurodegenerative Conditions By Selectively Removing Senescent Cells From Neurological TissueJun 7, 2022 · US 11,351,167Granted
- Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 InhibitorDec 9, 2021 · Application 17285420Pending
- Methods of Inhibiting Pathological AngiogenesisSep 28, 2021 · US 11,129,838Granted
- Acylsulfonamide Derivatives For Treating Senescence-associated Diseases And DisordersSep 7, 2021 · US 11,111,259Granted
- Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerApr 20, 2021 · US 10,981,892Granted
- Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerMar 11, 2021 · Application 16920131Pending
- Treating Cognitive Decline And Other Neurodegenerative Conditions By Selectively Removing Senescent Cells From Neurological TissueFeb 4, 2021 · Application 17066256Pending
- Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerDec 24, 2020 · Application 16920170Pending
- Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerDec 17, 2020 · Application 16888197Pending
- Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related ConditionsNov 19, 2020 · Application 16958620Pending
- Conjugates That Are Configured For Targeted Delivery Of Therapeutic Compounds To Senescent CellsAug 18, 2020 · US 10,745,445Granted
- Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating CancerAug 18, 2020 · US 10,745,429Granted
- Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating CancerAug 11, 2020 · US 10,738,042Granted
- Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerJul 21, 2020 · US 10,717,722Granted
- Acyl Phosphonamidates and Acyl Benzylamines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerJul 7, 2020 · US 10,703,745Granted
- Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerJun 23, 2020 · US 10,689,416Granted
- Technology to Inhibit Vascular Changes That Lead to Vision Loss in the EyeMar 17, 2020 · US 10,588,916Granted
- Chemical Entities That Kill Senescent Cells For Use In Treating Age-related DiseaseMar 5, 2020 · Application 16578130Pending
- Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerDec 31, 2019 · US 10,519,197Granted
- Compositions Of Matter For Treatment Of Ophthalmic Conditions By Selectively Removing Senescent Cells From The EyeNov 19, 2019 · US 10,478,432Granted
- Chemical Entities That Kill Senescent Cells For Use In Treating Age-related DiseaseOct 1, 2019 · US 10,426,788Granted
- Products Of Chiral Synthesis Of Cis-imidazoline Compounds And Their UseSep 5, 2019 · Application 16415862Pending
- Chiral Synthesis Method For Producing Cis-imidazoline Compounds For Pharmaceutical UseJun 25, 2019 · US 10,329,279Granted
- Chemical Compounds For Treating Atherosclerosis By Stabilizing Atherosclerotic Plaques Or Delaying AtherogenesisJun 13, 2019 · Application 16181163Pending
- Chemical Entities That Kill Senescent Cells For Use In Treating Age-related DiseaseFeb 5, 2019 · US 10,195,213Granted
- Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque RegressionJan 3, 2019 · Application 16025238Pending
- Treatment Of Ophthalmic Conditions By Selectively Removing Senescent Cells From The EyeJul 3, 2018 · US 10,010,546Granted
- Chiral Synthesis Method For Producing Cis-imidazoline Compounds For Pharmaceutical UseJun 5, 2018 · US 9,988,368Granted
- Drug Conjugates For Delivering Compounds To Senescent CellsMay 15, 2018 · US 9,969,776Granted
Related companies, and why
- Crossbow TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Phoenix Animal Wellness, Inc.Similar federal contract value in Biotech · null in contracts
- NABsys IncSimilar federal contract value in Biotech · null in contracts
- INFLAMED, INC.Similar federal contract value in Biotech · null in contracts
- Apellis Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- SOLVEXA, LLCSimilar federal contract value in Biotech · null in contracts
Press
Jocasta Signs UCSF Licensing Agreement to Advance α-klotho for Managing Cognitive ImpairmentPRNewswire
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .